Albany, NY -- (SBWire) -- 06/24/2019 --Prostate Cancer Market Insights, Epidemiology and Market Forecast-2028

1. Prostate Cancer is the most common type of cancer found in American men.
2. Nearly one in nine men will develop prostate cancer in his lifetime, though it is usually diagnosed after age 40.
3. Every 45 minutes one man dies from prostate cancer – i.e. more than 11,000 men every year.

DelveInsight launched a new report on Prostate Cancer Market Insights, Epidemiology and Market Forecast-2028

Key benefits

1. Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Prostate Cancer epidemiology and Prostate Cancer market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Prostate Cancer market report provides insights on the current and emerging therapies.
3. Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prostate Cancer market.
Request for sample pages

"Prostate Cancer highest incidence rates have been reported in North America, Oceania, and Northern and Western Europe."

The goals of pharmacotherapy for prostate cancer are to induce remission, reduce morbidity, and prevent complications. Agents used for the treatment of Prostate Cancer include the following: Androgen antagonists, Gonadotropin-releasing hormone (GnRH) agonists, Bisphosphonates, Antifungal agents, Chemo-therapeutic agents, Corticosteroids and Immunologic agents.
There are many prostate cancer unmet needs. Out of these, the lack of prostate cancer therapeutic options for non- metastatic castration-resistant prostate cancer (nmCRPC) patients and the need to delay the onset of castration-resistant disease in metastatic hormone-naïve prostate cancer (mHNPC) are two of the most pressing ones. Despite rapidly evolving therapeutic landscape for prostate cancer treatment, the diagnostic landscape has remained relatively static. Hence, there is a high unmet need for novel biomarkers that can demonstrate improvement in the cancer. Prostate cancer is a complex disease, with multiple subtypes and clinical presentations. Therefore, a better understanding of disease pathogenesis is required for the development of pharmacological therapies for prostate cancer treatment. Much progress has been made in recent years to understand the underlying genetic basis that drives prostate cancer. Such mechanistic information is useful for development of novel prostate cancer therapeutic targets, to identify biomarkers for early detection or to distinguish between aggressive and indolent disease, and to predict prostate cancer treatment outcome.
The factors that shall further expedite the growth of prostate cancer market during the forecast period of (2019-2028) include high incidence, increased morbidity rate due to prostate cancer and increasing awareness about available prostate cancer treatments.
Prostate Cancer market dynamics is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world and expected the launch of Prostate Cancer emerging therapies during the forecast period of 2019-2028. Companies across the globe are working towards the development of new Prostate Cancer treatment therapies like:-
1. Clovis Oncology
2. Tracon Pharmaceuticals
3. Eli Lilly
4. OncBioMune Pharmaceuticals
and many others

Drugs in the clinical trials are expected to propel the growth of the Prostate Cancer drugs market in the upcoming years are:-
1. Rucaparib
2. TRC253
3. LY2835219
4. ProscaVax
And many others

Table of contents

1. Report Introduction
2. Prostate Cancer Market Share at a glance
3. Prostate Cancer Disease Background and Overview
4. Prostate Cancer Epidemiology and Patient Population
5. Prostate Cancer Country Wise Epidemiology
5.1. United States
5.2. EU5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Prostate Cancer Current Treatment & Medical Practices
7. Prostate Cancer Marketed Drugs
8. CASODEX: AstraZeneca Pharmaceutical
9. ZYTIGA: Centocor Ortho Biotech
10. XTANDI: Astellas Pharma
11. Prostate Cancer Current Unmet Needs
12. Prostate Cancer Emerging Therapeutics
12.1. Key Cross Competition
12.2.Rucaparib: Clovis Oncology
12.3.TRC253: Tracon Pharmaceuticals
12.4.ProscaVax: OncBioMune Pharmaceuticals
13. Prostate Cancer Market Size
14. Prostate Cancer Region-Wise Market size
14.1.United States
14.2.EU-5
14.2.1. Germany
14.2.2. France
14.2.3. Italy
14.2.4. Spain
14.2.5. United Kingdom
14.3.Japan
15. Market Drivers
16. Market Barriers
17. Appendix
18. Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight